ImCare Biotech is structured around development of innovative technologies in the diagnosis and treatment of long term illnesses including hepatitis and liver cancer. The firm's main products in development are innovative diagnostic biomarkers, as well as developmental drugs for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The objective is to provide faster diagnosis and eventual treatment of the respective diseases than currently available alternatives. The first phase diagnostic product, Hepatodetect©, is based on research undertaken by one of the Founders - formerly a professor at Drexel Universitys Institute for Biotechnology and Virology - and discovery of a protein, SPIK, which has been demonstrated as an effective apoptosis inhibitor. The technology has shown promise in preliminary studies and is currently undergoing intensive clinical testing.
